By Chris Wack


Atea Pharmaceuticals Inc. reported positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate Covid-19.

Roche Holding AG and Atea are jointly developing AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform.

The biopharmaceutical company said the interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with Covid-19, of which data from 62 patients were evaluable for virology analysis.

Interim virology results indicated that AT-527 rapidly reduced viral load levels. At Day 2, patients receiving AT-527 experienced an 80% greater mean reduction from baseline viral load as compared with placebo. A sustained difference in viral load reduction was maintained through Day 8, the company said.

By Day 14, the last viral sampling study day, 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus. Nasopharyngeal swabs were measured in a reverse transcription polymerase chain reaction test for the quantitative detection of nucleic acid from SARS-CoV-2, the company said.

Consistent with previous studies, AT-527 was generally safe and well tolerated, the company said.

In this study, there were no drug-related serious adverse events. Nonserious adverse events were equally distributed across treatment arms. Most were mild-to-moderate in severity and assessed as not related to the study drug. No safety concerns or newly determined risks were identified, the company said.

Atea shares were up 5% to $25.43 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

June 30, 2021 07:37 ET (11:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Roche (QX) Charts.